Cellectis (CLLS) Return on Capital Employed (2015 - 2026)
Cellectis (CLLS) recorded quarterly Return on Capital Employed of 25.55% in Q1 2026, down 45.33% quarter-over-quarter from 17.58% in Q4 2025, and down 54.0% on a YoY basis from 55.55% in Q1 2025.
Cellectis (CLLS) Return on Capital Employed (2015 - 2026) Analysis & Trends
Cellectis' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 25.55% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 54.0% year-over-year to 25.55%; the TTM figure through Mar 2026 stood at 25.55% (down 54.0% YoY), while the FY2025 annual figure was 28.58%, up 234.0% from the prior year.
- Return on Capital Employed was 25.55% for Q1 2026 at Cellectis, down from 17.58% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 13.21% in Q3 2025 to a low of 83.28% in Q4 2023.
- Historically, Return on Capital Employed has averaged 37.18% across 5 years, with a median of 39.95% in 2024.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed plunged 4299 bps in 2023, then surged 5662 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 40.29% in 2022, then sank by 107 bps to 83.28% in 2023, then soared by 68 bps to 26.65% in 2024, then surged by 34 bps to 17.58% in 2025, then plunged by 45 bps to 25.55% in 2026.
- The last three Return on Capital Employed figures came in at 25.55% (Q1 2026), 17.58% (Q4 2025), and 13.21% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 450.31% |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 51.73% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -107.40% |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -50.43% |
| 10 | Cellectis | 17.40 Bn | 17.21 Bn | - | -25.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -25.55% |
| Dec 31, 2025 | -17.58% |
| Sep 30, 2025 | -13.21% |
| Jun 30, 2025 | -23.60% |
| Mar 31, 2025 | -25.01% |
| Dec 31, 2024 | -26.65% |
| Sep 30, 2024 | -33.26% |
| Jun 30, 2024 | -39.95% |
| Mar 31, 2024 | -50.97% |
| Dec 31, 2023 | -83.28% |
| Sep 30, 2023 | -42.00% |
| Jun 30, 2023 | -40.54% |
| Mar 31, 2023 | -39.29% |
| Dec 31, 2022 | -40.29% |
| Sep 30, 2022 | -43.87% |
| Jun 30, 2022 | -44.29% |
| Mar 31, 2022 | -42.79% |
| Dec 31, 2021 | -35.71% |
| Sep 30, 2021 | -36.02% |
| Jun 30, 2021 | -31.58% |